Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
|Videos|October 7, 2021
Study assesses the efficacy of Rezum water vapor therapy in treating BPH
Author(s)Urology Times staff
Advertisement
In this video, Dean Elterman, MD, MSc, FRCSC, discusses the background, findings, and takeaways of the study, “Rezūm water vapor therapy for large volume (≥80 mL) benign prostatic enlargement: large, multi-center cohort,” presented at the 2021 American Urological Association annual meeting. Elterman is an associate professor of urology at the University of Toronto and an attending urologist at the University Health Network, Toronto, Canada.
Advertisement
Related to this article
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
Advertisement
Advertisement